Latest news with #AdarPoonawalla
Time of India
07-05-2025
- Entertainment
- Time of India
Karan Johar breaks silence on selling 50 per cent of Dharma Productions to Adar Poonawalla for Rs 1000 crore: 'I needed funds to grow'
In 2024, made headlines when he sold a 50 percent stake of his production company, Dharma Productions , to CEO for a staggering Rs 1,000 crore. In a recent conversation with Raj Shamani, the filmmaker opened up about the motivation behind the move, citing the need for growth and long-term expansion. Tired of too many ads? go ad free now Inherited his father 's reputation, not financial security Speaking about the evolution of Productions, admitted that while his father Yash Johar founded the company, its success only began post-1998 with his directorial debut Kuch Kuch Hota Hai. 'Before Kuch Kuch Hota Hai, we had five flops in a row. What I inherited from my father was goodwill, not money,' Karan shared, highlighting how the emotional and reputational legacy of his father fueled his journey, not a financial head start. Karan also reflected on the earlier collaborative model of filmmaking at Dharma, revealing that most profits had to be shared with partners. 'We couldn't finance films on our own ability, so our biggest hits had partners. But I wanted profitability to stay within Dharma. That's when I stopped doing collaborative projects,' he said. Post-1998, hits like Kabhi Khushi Kabhie Gham, Kal Ho Naa Ho, and Kabhi Alvida Naa Kehna turned the tide for Dharma Productions. But it wasn't an easy journey. After the death of his father in 2004, Karan leaned on his childhood friend and current CEO of Dharma, . 'He left his life in London overnight to help me. Till date, I have zero business acumen, but a strong instinct. Apoorva handles the business, I handle the creative,' Karan added. Strategic partnership with Adar Poonawalla Explaining why he brought Adar Poonawalla on board as an equity partner, Karan said, 'In 2023, we realised we had to scale. Tired of too many ads? go ad free now Organic growth would have taken us 5–7 more years. We needed capital. Today, I'm very happy with Adar. He's a wonderful human being with sharp instincts. Now I feel accountable—this is someone else's money. I have to deliver success.' Karan Johar Snapped in White Tee and Joggers During Shoot Karan also addressed criticisms that Dharma didn't have a particularly profitable 2024. 'Kill was critically appreciated, Mr & Mrs Mahi made money, Bad Newz was profitable, Jigra broke even. We're now producing our first Punjabi film Akaal, and Dhadak 2 is coming soon. We're bullish,' he asserted. Reflecting on the highs and lows of showbiz, Karan concluded with characteristic candour: 'I don't take success seriously or failure to heart. I don't mind a flop. I just don't like average films. If I'm wrong, tell me—I'll learn and move forward.'
Entrepreneur
07-05-2025
- Business
- Entrepreneur
TPG to Acquire 35% Stake in SCHOTT Poonawalla from Serum Institute of India
The transaction is expected to close in the first half of 2025. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Global investment firm TPG has entered into a binding agreement to acquire a 35% stake in SCHOTT Poonawalla Pvt Ltd, a leading drug packaging joint venture between Germany's SCHOTT Pharma and Serum Institute of India (SII), part of the Cyrus Poonawalla Group. SCHOTT Pharma, which focuses on drug containment and delivery systems, announced the deal and confirmed it would retain its 50% stake in the JV. Serum Institute will continue to hold a minority interest after the transaction. The deal is being funded by TPG Growth and co-investor Novo Holdings. Financial terms were not disclosed. The transaction is expected to close in the first half of 2025, subject to regulatory approvals and customary conditions. SCHOTT Poonawalla manufactures critical packaging products such as vials, syringes, and cartridges—vital components in the injectable drug and vaccine ecosystem. The JV serves a growing pharmaceutical market driven by rising demand for biologics and vaccines. "Having TPG join the partnership alongside SCHOTT Pharma and Serum Institute of India represents a significant milestone," the companies said in a joint statement. TPG, which manages USD 246 billion in assets, considers healthcare a core investment theme. "We are excited to partner with SCHOTT Pharma and Serum Institute and build upon SCHOTT Poonawalla's market leadership," said Bhushan Bopardikar, Business Unit Partner at TPG Growth. Adar Poonawalla, CEO of Serum Institute, added, "Their experience in healthcare investing and global network make them a strong partner." Jefferies and AZB & Partners advised on the deal, with J. Sagar Associates handling legal aspects.
&w=3840&q=100)
Business Standard
06-05-2025
- Business
- Business Standard
TPG acquires 35% in SCHOTT Poonawalla, SII retains minority stake
SCHOTT Pharma, a global player in drug containment and delivery solutions, announced on Tuesday that global investment firm TPG has acquired a 35 per cent stake in its Indian joint venture, SCHOTT Poonawalla, from the Serum Institute of India (SII). The investment, made through TPG Growth — the firm's middle-market and growth equity platform — includes Novo Holdings as a co-investor. Post-transaction, SCHOTT Pharma will continue to hold 50 per cent of the joint venture, while SII will retain a minority stake. The infusion of capital and expertise from TPG is expected to drive the company's next phase of growth and strengthen its position in the global pharmaceutical supply chain. The transaction, subject to customary closing conditions, is expected to be completed in the first half of 2025. SCHOTT Poonawalla, a collaboration between SCHOTT Pharma and SII — the world's largest vaccine manufacturer and part of the Cyrus Poonawalla Group — manufactures advanced drug containment systems, including cartridges for auto-injector pens, prefillable syringes, vials, and ampoules. It also provides regulatory services to pharma and biotech clients, including CDMOs (contract development and manufacturing organisations). Commenting on the development, Bhushan Bopardikar, business unit partner at TPG Growth, said: 'SCHOTT Poonawalla has established itself as a market leader with a world-class manufacturing base in India. We are excited to partner with SCHOTT Pharma and SII to accelerate the company's growth and innovation.' Adar Poonawalla, CEO of SII, said that while the company is partially exiting the joint venture, it will continue its collaboration with SCHOTT Pharma. 'TPG brings healthcare investing experience and a global network, which makes them a strong partner as SCHOTT Poonawalla scales and explores new opportunities,' he said. SCHOTT Pharma's CEO Andreas Reisse said India remains a key strategic manufacturing base for the company. 'Welcoming TPG to this partnership strengthens our presence in the Indian market and enhances our global reach,' he added. Ashok Saxena, managing director of SCHOTT Poonawalla, added that the company is focused on next-generation drug delivery systems. 'We're confident that TPG's track record in healthcare in India will be invaluable.' Jefferies advised TPG on the deal, with AZB & Partners and J Sagar Associates serving as legal advisors.
Mint
06-05-2025
- Business
- Mint
TPG acquires 35% stake in Schott Pharma from Serum Institute
US private equity firm TPG has entered into a binding agreement to acquire a 35% stake in the SCHOTT Poonawalla joint venture from Serum Institute of India (SII), the firms announced on Tuesday. TPG Growth, TPG's middle market and growth equity platform, is funding the investment, along with Novo Holdings as a co-investor. Following the transaction, SII will retain a minority stake in SCHOTT Poonawalla. The total investment from TPG and Novo Holdings amounts to $300 million, according to one person with knowledge of the development. The partnership with TPG will aid the joint venture to scale up, 'equipping the company with additional resources and strategic insight to support its long-term global ambitions,' the companies said in a statement, adding that the deal was likely to close in the first half of 2025. Serum Institute of India had entered into a joint venture with SCHOTT Pharma, a German pioneer in drug containment and delivery solutions, in 2021. 'Partnering with TPG marks an important step for us,' Adar Poonawalla, chief executive of Serum Institute of India, said in the statement. 'Their experience in healthcare investing and global network make them a strong partner as we scale and explore new opportunities. Our collaboration with SCHOTT Pharma will continue, ensuring supply chain resilience and advancing innovation in vaccine packaging and delivery,' he added. Ashok Saxena, managing director of SCHOTT Poonawalla, said the entity was seeing increasing demand from pharmaceutical customers for advanced drug delivery and discovery solutions as they expand operations and shift towards more innovation and complex drug sales. 'We are excited to welcome TPG onboard as an investor, and are confident that their proven track record of successfully driving healthcare businesses in the Indian market will greatly benefit SCHOTT Poonawalla,' he added. SCHOTT Poonawalla designs advanced drug containment and delivery solutions for pharmaceutical and biotechnology customers. The company's portfolio includes cartridges for auto-injector pens, prefillable syringes for a wide variety of biologics, vials, ampoules, as well as regulatory services for biotech and pharmaceutical companies, and contract development and manufacturing organizations. SCHOTT Pharma, which has more than 1,800 customers, generated revenue of €957 million in FY24. 'We are excited to partner with SCHOTT Pharma and Serum Institute of India and build upon SCHOTT Poonawalla's market leadership position as India's largest injectables-focused drug containment solutions company,' Bhushan Bopardikar, business unit partner at TPG Growth, said in the statement. 'SCHOTT Pharma's innovation capabilities and pure-play focus on injectables will be complemented by TPG's local market expertise, relationships, and experience from its strong presence in the Indian healthcare sector,' added Andreas Reisse, CEO at SCHOTT Pharma. 'As we continue to expand our local production capacities and leading role in that, this step will further enhance our global footprint and deliver exceptional value to our customers.' First Published: 6 May 2025, 12:20 PM IST
Time of India
06-05-2025
- Business
- Time of India
TPG to acquire 35% stake in SCHOTT Poonawalla from Serum Institute of India
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel TPG has agreed to acquire a 35% stake in drug containment firm SCHOTT Poonawalla from Serum Institute of India (SII). The decision was announced on Tuesday, and the acquisition is being led by TPG Growth—TPG's middle-market and growth equity platform—with Denmark-based Novo Holdings joining as a the deal closes, Serum Institute will retain a minority holding in SCHOTT Poonawalla, while SCHOTT Pharma continues as the controlling Poonawalla, a joint venture between German specialty glassmaker SCHOTT Pharma and SII—part of the Cyrus Poonawalla Group—manufactures a wide range of advanced containment and delivery systems including vials, prefillable syringes, ampoules, and cartridges for auto-injector pens. The company also provides regulatory services and works closely with CDMOs (Contract Development and Manufacturing Organisations).TPG's investment is intended to support the company's growth ambitions both in India and globally.'Partnering with TPG marks an important step for us. Their experience in healthcare investing and global network make them a strong partner as we scale and explore new opportunities. Our collaboration with SCHOTT Pharma will continue, ensuring supply chain resilience and advancing innovation in vaccine packaging and delivery,' said Adar Poonawalla, CEO of Serum Institute of India.'We are excited to partner with SCHOTT Pharma and Serum Institute of India and build upon SCHOTT Poonawalla's market leadership position as India's largest injectables-focused drug containment solutions company,' said Bhushan Bopardikar, Business Unit Partner at TPG Growth. 'On the back of a world-class manufacturing infrastructure in India, SCHOTT Poonawalla has developed an industry leading reputation... for over two decades.'The move comes at a time when pharmaceutical companies are ramping up capacity for biologics and complex injectable drugs, with demand for high-quality packaging solutions rising Pharma CEO Andreas Reisse said India remains a 'strategically important manufacturing hub' for the company.'Welcoming TPG to the partnership marks an exciting step forward in our collaboration,' Reisse said. 'TPG's local market expertise, relationships, and experience from its strong presence in the Indian healthcare sector... will further enhance our global footprint.'Ashok Saxena, Managing Director at SCHOTT Poonawalla, highlighted the company's role in supplying next-generation drug delivery systems. 'We are excited to welcome TPG onboard... their proven track record of successfully driving healthcare businesses in the Indian market will greatly benefit SCHOTT Poonawalla,' he deal is expected to close in the first half of 2025, subject to regulatory approvals and customary closing conditions.
